A new report from the US Department of Health and Human Services Office of the Inspector General (OIG) highlights challenges faced by the US Food and Drug Administration and industry alike during the country’s initial struggles with the COVID-19 pandemic.
The report assesses how the FDA used its Emergency Use Authorization (EUA) authority to assess the first COVID-19 tests between January and May of 2020. To conduct the review, OIG...